Effects of prenatal hypoxia on schizophrenia-related phenotypes in heterozygous reeler mice: A gene × environment interaction study

European Neuropsychopharmacology

Volumn 24, Issue 8, 2014, Pages 1324-1336

  Howell, Kristy R ^a   Pillai, Anilkumar ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Mice; Prenatal hypoxia; Reelin; Schizophrenia; VEGF

Indexed keywords

CORTICOSTERONE; GLUCOCORTICOID RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN; REELIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; HIF1A PROTEIN, MOUSE; NERVE CELL ADHESION MOLECULE; NERVE PROTEIN; REELIN PROTEIN; SCLEROPROTEIN; SERINE PROTEINASE; VASCULOTROPIN A;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR; BRAIN BLOOD FLOW; BRAIN REGION; BRAIN SIZE; CORTICOSTERONE BLOOD LEVEL; EMBRYO; ENVIRONMENTAL FACTOR; FETUS HYPOXIA; FRONTAL CORTEX; GENETIC RISK; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HEREDITY; HETEROZYGOTE; HIPPOCAMPUS; MOUSE; NONHUMAN; OPEN FIELD TEST; PATHOPHYSIOLOGY; PHENOTYPE; PRENATAL PERIOD; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SCHIZOPHRENIA; SENSORY GATING; SPATIAL MEMORY; WILD TYPE; Y-MAZE TEST; ANALYSIS OF VARIANCE; ANIMAL; ANOXIA; AUDITORY STIMULATION; BLOOD; BLOOD FLOW; COMPLICATION; FEMALE; FRONTAL LOBE; GENE EXPRESSION REGULATION; GENETICS; GENOTYPING TECHNIQUE; INHIBITION (PSYCHOLOGY); MAZE TEST; METABOLISM; MOUSE MUTANT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHYSIOLOGY; PREGNANCY; PRENATAL EXPOSURE; PSYCHOPHYSICS;

ACOUSTIC STIMULATION; ANALYSIS OF VARIANCE; ANIMALS; ANOXIA; CELL ADHESION MOLECULES, NEURONAL; CORTICOSTERONE; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FRONTAL LOBE; GENE EXPRESSION REGULATION; GENE-ENVIRONMENT INTERACTION; GENOTYPING TECHNIQUES; HIPPOCAMPUS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INHIBITION (PSYCHOLOGY); MAGNETIC RESONANCE IMAGING; MAZE LEARNING; MICE; MICE, NEUROLOGIC MUTANTS; NERVE TISSUE PROTEINS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PSYCHOACOUSTICS; REGIONAL BLOOD FLOW; SCHIZOPHRENIA; SERINE ENDOPEPTIDASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84905037077     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.05.011     Document Type: Article

References (49)

1. Acri J.B., Morse D.E., Popke E.J., Grunberg N.E. Nicotine increases sensory gating measured as inhibition of the acoustic startle reflex in rats. Psychopharmacol. (Berl). Mar. 1994, 114(2):369-374.
2. Andreasen N., O'Leary D., Flaum M., Nopoulos P., Watkins G., Ponto L., Hichwa R. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet 1997, 349:1730-1734.
3. Andreasen N.C., Liu D., Ziebell S., Vora A., Ho B.C. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am. J. Psychiatry 2013, 170(6):609-615.
4. Arany Z., Foo S.Y., Ma Y., Ruas J.L., Bommi-Reddy A., Girnun G., Cooper M., Laznik D., Chinsomboon J., Rangwala S.M., Baek K.H., Rosenzweig A., Spiegelman B.M. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 2008, 451:1008-1012.
5. Asami T., Bouix S., Whitford T.J., Shenton M.E., Salisbury D.F., McCarley R.W. Longitudinal loss of gray matter volume in patients with first-episode schizophrenia: DARTEL automated analysis and ROI validation. Neuroimage 2012, 59(2):986-996.
6. Baburamani A.A., Ek C.J., Walker D.W., Castillo-Melendez M. Vulnerability of the developing brain to hypoxic-ischemic damage: contribution of the cerebral vasculature to injury and repair. Front. Physiol. 2012, 3:424.
7. Berra E., Pagès G., Pouysségur J. MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev. 2000, 19(1-2):139-145.
8. Braff D.L., Grillon C., Geyer M.A. Gating and habituation of the startle reflex in schizophrenic patients. Arch. Gen. Psychiatry 1992, 49(3):206-215.
9. Bunn H.F., Poyton R.O. Oxygen sensing and molecular adaptation to hypoxia. Physiol. Rev. 1996, 76(3):839-885.
10. Cannon M., Jones P.B., Murray R.M. Obstetric complications and schizophrenia: historical and meta-analytic review. Am. J. Psychiatry. 2002, 159(7):1080-1092.
11. Choy K.H., van den Buuse M. Attenuated disruption of prepulse inhibition by dopaminergic stimulation after maternal deprivation and adolescent corticosterone treatment in rats. Eur Neuropsychopharmacol. 2008, 18(1):1-13.
12. Costa E., Davis J., Pesold C., Tueting P., Guidotti A. The heterozygote reeler mouse as a model for the development of a new generation of antipsychotics. Curr. Opin. Pharmacol. Feb. 2002, 2(1):56-62.
13. David D.J., Samuels B.A., Rainer Q., Wang J.W., Marsteller D., Mendez I., Drew M., Craig D.A., Guiard B.P., Guilloux J.P., et al. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 2009, 62:479-493.
14. de Kloet E.R., Sibug R.M., Helmerhorst F.M., Schmidt M.V. Stress, genes and the mechanism of programming the brain for later life. Neurosci. Biobehav. Rev. 2005, 29(2):271-281.
15. Demjaha A., MacCabe J.H., Murray R.M. How genes and environmental factors determine the different neurodevelopmental trajectories of schizophrenia and bipolar disorder. Schizophrenia Bull. 2011, 38(2):209-214.
16. Duncan E.J., Szilagyi S., Efferen T.R., Schwartz M.P., Parwani A., Chakravorty S., Madonick S.H., Kunzova A., Harmon J.W., Angrist B., et al. Effect of treatment status on prepulse inhibition of acoustic startle in schizophrenia. Psychopharmacol. (Berl). 2003, 167(1):63-71.
17. Duncan G.E., Moy S.S., Perez A., Eddy D.M., Zinzow W.M., Lieberman J.A., Snouwaert J.N., Koller B.H. Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav. Brain Res. 2004, 153(2):507-519.
18. Eells J.B., Misler J.A., Nikodem V.M. Early postnatal isolation reduces dopamine levels, elevates dopamine turnover and specifically disrupts prepulse inhibition in Nurr1-null heterozygous mice. Neuroscience 2006, 140(4):1117-1126.
19. Ellenbroek B.A., Cools A.R. Early maternal deprivation and prepulse inhibition: the role of the postdeprivation environment. Pharmacol. Biochem. Behav. 2002, 73(1):177-184.
20. Fatemi S.H., Earle J.A., McMenomy T. Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression. Mol. Psychiatry 2000, 5(6):654-663.
21. Flores B.H., Kenna H., Keller J., Solvason H.B., Schatzberg A.F. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 2006, 31(3):628-636.
22. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol. 1996, 16(9):4604-4613.
23. Fulzele S., Pillai A. Decreased VEGF mRNA expression in the dorsolateral prefrontal cortex of schizophrenia subjects. Schizophr. Res. 2009, 115(2-3):372-373.
24. Geyer M.A., McIlwain K.L., Paylor R. Mouse genetic models for prepulse inhibition: an early review. Mol. Psychiatry. 2002, 7(10):1039-1053.
25. Giordano F.J., Johnson R.S. Angiogenesis: the role of the microenvironment in flipping the switch. Curr. Opin. Genet. Dev. 2001, 11(1):35-40.
26. Golan M.H., Mane R., Molczadzki G., Zuckerman M., Kaplan-Louson V., Huleihel M., Perez-Polo J.R. Impaired migration signaling in the hippocampus following prenatal hypoxia. Neuropharmacology 2009, 57(5-6):511-522.
27. Greenberg D.A., Jin K. From angiogenesis to neuropathology. Nature 2005, 438:954-959.
28. Hanson D.R., Gottesman I.I. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med. Genet. 2005, 6-7.
29. Haukvik U.K., Saetre P., McNeil T., Bjerkan P.S., Andreassen O.A., Werge T., Jönsson E.G., Agartz I. An exploratory model for G×E interaction on hippocampal volume in schizophrenia; obstetric complications and hypoxia-related genes. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34(7):1259-1265.
30. Howell K.R., Kutiyanawalla A., Pillai A. Long-term continuous corticosterone treatment decreases VEGF receptor-2 expression in frontal cortex. PLoS One 2011, 6(5):e20198.
31. Impagnatiello, F., Guidotti, A.R., Pesold, C., Dwivedi, Y., Caruncho, H., Pisu, M.G., Uzunov, D.P., Smalheiser, N.R., Davis, J.M., Pandey, G.N., Pappas, G.D., Tueting, P., Sharma, R.P., Costa, E. 1998. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. In: Proceedings of the National Academy of Sciences of the United States of America. 95 (26), pp. 15718-15723.
32. Jin, K., Zhu, Y., Sun, Y., Mao, X.O., Xie, L., Greenberg, D.A. 2002. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. In: Proceedings of the National Academy of Sciences of the United States of America. 99, pp. 11946-11950.
33. Kutiyanawalla A., Promsote W., Terry A., Pillai A. Cysteamine treatment ameliorates alterations in GAD67 expression and spatial memory in heterozygous reeler mice. Int. J. Neuropsychopharmacol. 2012, 15(8):1073-1086.
34. Levy A.P., Levy N.S., Wegner S., Goldberg M.A. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J. Biol. Chem. 1995, 270(22):13333-13340.
35. Mayoral S.R., Omar G., Penn A.A. Sex differences in a hypoxia model of preterm brain damage. Pediatr. Res. 2009, 66(3):248-253.
36. Nicodemus K.K., Marenco S., Batten A.J., Vakkalanka R., Egan M.F., Straub R.E., Weinberger D.R. Serious obstetric complications interact with hypoxia-regulated/vascular-expression genes to influence schizophrenia risk. Mol. Psychiatry 2008, 13(9):873-877.
37. Nullmeier S., Panther P., Dobrowolny H., Frotscher M., Zhao S., Schwegler H., Wolf R. Region-specific alteration of GABAergic markers in the brain of heterozygous reeler mice. Eur. J. Neurosci. 2011, 33(4):689-698.
38. Oliver P.L., Davies K.E. Interaction between environmental and genetic factors modulates schizophrenic endophenotypes in the Snap-25 mouse mutant blind-drunk. Hum. Mol. Genet. 2009, 18(23):4576-4589.
39. Paylor R., Crawley J.N. Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology (Berl). 1997, 132(2):169-180.
40. Podhorna J., Didriksen M. The heterozygous reeler mouse: behavioural phenotype. Behav. Brain Res. 2004, 153(1):43-54.
41. Qiu S., Korwek K.M., Pratt-Davis A.R., Peters M., Bergman M.Y., Weeber E.J. Cognitive disruption and altered hippocampus synaptic function in Reelin haploinsufficient mice. Neurobiol. Learn. Mem. 2006, 85(3):228-242.
42. Quinn, T.P., Peters, K.G., De Vries, C., Ferrara, N., Williams, L.T. 1993. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. In: Proceedings of the National Academy of Sciences of the United States of America. 90, pp. 7533-7537.
43. Salinger W.L., Ladrow P., Wheeler C. Behavioral phenotype of the reeler mutant mouse: effects of RELN gene dosage and social isolation. Behav. Neurosci. 2003, 117(6):1257-1275.
44. Schreiber R., Dalmus M., De Vry J. Effects of alpha 4/beta 2- and alpha 7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice. Psychopharmacology (Berl) 2002, 159(3):248-257.
45. 2 homeostasis. Curr. Opin. Genet. Dev. 1998, 8(5):588-594.
46. Semenza G.L. Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. Trends Mol. Med. 2012, 18(9):534-543.
47. Tueting P., Costa E., Dwivedi Y., Guidotti A., Impagnatiello F., Manev R., Pesold C. The phenotypic characteristics of heterozygous reeler mouse. Neuroreport 1999, 10(6):1329-1334.
48. Van Erp T.G., Saleh P.A., Rosso I.M., Huttunen M., Lönnqvist J., Pirkola T., Salonen O., Valanne L., Poutanen V.P., Standertskjöld-Nordenstam C.G., Cannon T.D. Contributions of genetic risk and fetal hypoxia to hippocampal volume in patients with schizophrenia or schizoaffective disorder, their unaffected siblings, and healthy unrelated volunteers. Am. J. Psychiatry 2002, 159:1514-1520.
49. Zachary I. Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neurosignals 2005, 14:207-221.